Evolent Health could see $35 a share or more in a takeover - analyst

seekingalpha08-23

Evolent Health (NYSE:EVH) could see $35 a share in a takeover from a private equity firm, according to a Truist analyst, after a report that the company is in talks for a sale after takeover interest....

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2461560164?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1267661932/image_1267661932.jpg","is_english":true,"pubTime":"2024-08-23 19:48","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2461560164","market":"sh","top_or_hot":-1,"title":"Evolent Health could see $35 a share or more in a takeover - analyst","media":"seekingalpha","content":"<div>\n<p>Evolent Health (NYSE:EVH) could see $35 a share in a takeover from a private equity firm, according to a Truist analyst, after a report that the company is in talks for a sale after takeover interest....</p>\n\n<a href=\"https://seekingalpha.com/news/4143236-evolent-health-could-see-35-a-share-or-more-in-a-takeover-analyst\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evolent Health could see $35 a share or more in a takeover - analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvolent Health could see $35 a share or more in a takeover - analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-23 19:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4143236-evolent-health-could-see-35-a-share-or-more-in-a-takeover-analyst><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Evolent Health (NYSE:EVH) could see $35 a share in a takeover from a private equity firm, according to a Truist analyst, after a report that the company is in talks for a sale after takeover interest....</p>\n\n<a href=\"https://seekingalpha.com/news/4143236-evolent-health-could-see-35-a-share-or-more-in-a-takeover-analyst\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0878866978.SGD","symbol_name":"First Eagle Amundi International AHS-QD SGD-H","start_time":0,"source_url":"https://seekingalpha.com/news/4143236-evolent-health-could-see-35-a-share-or-more-in-a-takeover-analyst","article_id":"2461560164","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1267661932/image_1267661932.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2461560164","pubTimestamp":1724413733,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Evolent Health  could see $35 a share in a takeover from a private equity firm, according to a Truist analyst, after a report that the company is in talks for a sale after takeover interest. Evolent  shares surged 14% on Thursday after Reuters reported that PE firms TPG , KKR  and CD&R are among parties that have expressed interest in a possible deal. Health insurer Elevance Health  is also among the bidders who may team up with a PE firm for a deal. \"We have always believed that an LBO transaction likely made more sense for EVH than a strategic transaction involving a health insurer, given the risk around EVH's health insurance partnerships resulting in conflict of interest,\" Truist analyst Jailendra Singh wrote in a note on Friday. A PE firm can pay ~$35 a share and generate a \"reasonable\" IRR and MOIC, Singh, who has a buy rating and $33 price target on Evolent  added. At that price, a PE shop could generate an IRR of around 20% and MOIC of ~2.5x. \"However, a joint partnership invol","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU1815333072.USD":"THREADNEEDLE (LUX) GLOBAL FOCUS \"AUP\" (USD) INC","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H","TPG":"TPG, Inc.","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","BK4135":"资产管理与托管银行","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1935042488.USD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (USD) INC","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","KKR":"KKR & Co L.P.","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0061474960.USD":"天利环球焦点基金AU Acc","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1935042215.USD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (USD) INC A","BK4585":"ETF&股票定投概念","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0251142724.SGD":"Fidelity America A-SGD","LU0106831901.USD":"贝莱德世界金融基金A2","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU1935043023.USD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME \"AA\" (USD) INC A","LU0882574055.USD":"富达全球健康医疗A ACC","EVH":"Evolent Health Inc","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4588":"碎股","LU0122379950.USD":"贝莱德世界健康科学A2","LU0957791311.USD":"THREADNEEDLE (LUX) GLOBAL FOCUS \"ZU\" (USD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","ELV":"Elevance Health"},"translate_title":"Evolent Health的收购价格可能达到每股35美元或更高——分析师","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TPG":1,"ELV":1,"EVH":1,"KKR":1},"content_text":"Evolent Health (NYSE:EVH) could see $35 a share in a takeover from a private equity firm, according to a Truist analyst, after a report that the company is in talks for a sale after takeover interest. Evolent (EVH) shares surged 14% on Thursday after Reuters reported that PE firms TPG (TPG), KKR (KKR) and CD&R are among parties that have expressed interest in a possible deal. Health insurer Elevance Health (ELV) is also among the bidders who may team up with a PE firm for a deal. \"We have always believed that an LBO transaction likely made more sense for EVH than a strategic transaction involving a health insurer, given the risk around EVH's health insurance partnerships resulting in conflict of interest,\" Truist analyst Jailendra Singh wrote in a note on Friday. A PE firm can pay ~$35 a share and generate a \"reasonable\" IRR and MOIC, Singh, who has a buy rating and $33 price target on Evolent (EVH) added. At that price, a PE shop could generate an IRR of around 20% and MOIC of ~2.5x. \"However, a joint partnership involving a strategic buyer such as ELV and a PE firm might have flexibility to push the purchase price higher,\" Singh wrote.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2461560164"}